We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

98 hedge funds and large institutions have $79.2M invested in DiaMedica Therapeutics in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 24 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 12

37% more call options, than puts

Call options by funds: $194K | Put options by funds: $142K

17% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 24

7% more funds holding

Funds holding: 92 → 98 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.68% less ownership

Funds ownership: 23.15% → 22.46% (-0.68%)

18% less capital invested

Capital invested by funds: $96M → $79.2M (-$16.8M)

Holders
98
Holders Change
+6
Holders Change %
+6.52%
% of All Funds
1.21%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
20
Increased
28
Reduced
24
Closed
12
Calls
$194K
Puts
$142K
Net Calls
+$52K
Net Calls Change
-$40K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.32M
2
Osaic Holdings
Osaic Holdings
Arizona
+$576K
3
ECM
ExodusPoint Capital Management
New York
+$476K
4
CI
Corient IA
Florida
+$475K
5
SEI Investments
SEI Investments
Pennsylvania
+$441K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$3.5M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$825K
3
FAM
Fred Alger Management
New York
-$662K
4
Goldman Sachs
Goldman Sachs
New York
-$555K
5
Barclays
Barclays
United Kingdom
-$368K
Name Holding Trade Value Shares
Change 		Change in
Stake
CLG
1
Cooperman Leon G
$13.7M – – –
BlackRock
2
BlackRock
New York
$12.6M -$354K -44,712 -2%
Millennium Management
3
Millennium Management
New York
$6.33M +$1.32M +167,032 +22%
PAPAIJV
4
Paragon Associates & Paragon Associates II Joint Venture
Texas
$5.92M – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$5.29M +$129K +16,261 +2%
State Street
6
State Street
Massachusetts
$4.36M +$130K +16,440 +3%
First Manhattan
7
First Manhattan
New York
$3.08M +$396K +50,000 +12%
BL
8
Bleichroeder LP
New York
$2.59M – – –
Northern Trust
9
Northern Trust
Illinois
$2.29M +$103K +12,999 +4%
VCM
10
Vanguard Capital Management
Pennsylvania
$2.26M +$2.64M +333,456 New
Osaic Holdings
11
Osaic Holdings
Arizona
$2.16M +$576K +72,703 +29%
LPL Financial
12
LPL Financial
California
$1.53M +$229K +28,900 +15%
VPM
13
Vanguard Portfolio Management
Pennsylvania
$1.38M +$1.61M +203,459 New
VFT
14
Vanguard Fiduciary Trust
Pennsylvania
$1.27M +$1.49M +187,724 New
Citadel Advisors
15
Citadel Advisors
Florida
$987K +$277K +34,987 +32%
SEI Investments
16
SEI Investments
Pennsylvania
$754K +$441K +55,660 +100%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$752K -$78.4K -9,898 -8%
Morgan Stanley
18
Morgan Stanley
New York
$714K -$3.5M -442,190 -81%
MW
19
Members Wealth
Pennsylvania
$656K – – –
EI
20
EAM Investors
California
$619K – – –
Charles Schwab
21
Charles Schwab
California
$599K -$67K -8,459 -9%
N
22
Nuveen
North Carolina
$536K -$253K -31,918 -29%
MCA
23
Magnolia Capital Advisors
Mississippi
$524K – – –
BTI
24
Blue Trust Inc
Georgia
$468K – – –
KCM
25
Kalehua Capital Management
Texas
$423K -$260K -32,871 -34%
1
2 3 4 5

DMAC Hedge Fund Activity: Q1 2026 in Review

98 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2026, worth a combined $79.2M — down 18% from $96M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new DMAC positions and 12 closed out — a net gain of 8 holders — while 28 added to existing stakes and 24 trimmed.

The largest buyer was Millennium Management, adding an estimated $1.32M. The largest seller was Morgan Stanley, cutting an estimated $3.5M.

  • 98 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2026, up from 92 in Q4 2025.
  • Funds reported $79.2M of DiaMedica Therapeutics stock for Q1 2026, down 18% quarter-over-quarter.
  • 20 funds opened new DiaMedica Therapeutics positions in Q1 2026 and 12 closed out, a net change of +8 holders.
  • The largest DiaMedica Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $1.32M added.
  • The largest DiaMedica Therapeutics seller in Q1 2026 was Morgan Stanley, an estimated $3.5M sold.

Based on aggregated 13F filings for Q1 2026.